Home > Healthcare > Pharmaceuticals > Active Pharmaceutical Ingredients > Montelukast Sodium Market

Montelukast Sodium Market Size

  • Report ID: GMI9309
  • Published Date: Apr 2024
  • Report Format: PDF

Montelukast Sodium Market Size

Montelukast Sodium Market size was valued at around USD 670.7 million in 2023 and is estimated to grow at 11.4% CAGR from 2024 to 2032. Montelukast sodium is a medication primarily used for the treatment of asthma and allergic rhinitis. It belongs to a class of drugs known as leukotriene receptor antagonists, work by blocking the action of leukotrienes, substances in the body that contribute to inflammation, bronchoconstriction and other symptoms associated with asthma and allergies.

 

The increasing prevalence of respiratory diseases includes asthma, allergic rhinitis serves as a substantial impetus for market growth. For instance, according to the World Health Organization (WHO), in 2019, asthma impacted approximately 262 million individuals worldwide and also led to 455,000 deaths during the same period. Thus, this underscores the need for effective pharmaceutical interventions such as montelukast sodium, plays a crucial role in managing conditions such as asthma and allergic rhinitis, thereby alleviating symptoms, improving quality of life, and potentially reducing mortality rates associated with these respiratory diseases. Furthermore, advancements in drug delivery and growing awareness and diagnosis are the promoting factors fostering the growth of the market.

 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Montelukast sodium market size was USD 670.7 million in 2023 and is expected to register 11.4% CAGR from 2024-2032 owing to the increasing prevalence of respiratory diseases includes asthma, allergic rhinitis worldwide.

Montelukast sodium industry from the montelukast sodium amorphous segment reached USD 387.6 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to having a higher solubility than their crystalline counterparts.

U.S. montelukast sodium industry is expected to register 11.1% CAGR from 2024-2032 due to the presence of highly developed healthcare infrastructure with advanced medical facilities and a robust pharmaceutical industry in the region.

Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd, Merck & Co., Inc., Morepen Laboratories Limited, Mylan N.V., Sandoz AG, Sanofi, Sun Pharma Industries Limited., and Teva Pharmaceutical Industries Limited, are some of the major montelukast sodium companies worldwide.

Montelukast Sodium Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 273
  • Countries covered: 23
  • Pages: 190
 Download Free Sample